Deerfield/ Dana-Farber’s USD 130 Million Cancer Research Deal; FDA-Approval to BMS’ Breyanzi & TG Therapeutics’ Ukoniq; EU Marketing Rights for ViiV Healthcare’s Rukobia
Delveinsight
FEBRUARY 9, 2021
Breyanzi will come with a price tag of USD 410,300 wholesale price, said the company, justifying it after taking into consideration several factors including medical and clinical value, patient value, and societal value. European Marketing Authorisation to ViiV Healthcare’s Rukobia for Multidrug-resistant HIV.
52 
Let's personalize your content